Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.35 |
| ▸ | PDE4A | P27815 | 6/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3881992 | 0.91 | FFAR4 (0.45) | HDAC1HDAC2S1PR1FFAR4PDE4B | |
| SCHEMBL3889227 | 0.90 | HRH3 (0.41) | HDAC1HDAC2HRH3S1PR1FFAR4 | |
| SCHEMBL3881678 | 0.89 | HRH3 (0.40) | HDAC1HDAC2HRH3S1PR1FFAR4 | |
| SCHEMBL3882431 | 0.83 | ADRB1 (0.36) | S1PR1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3881978 | 0.82 | HRH3 (0.41) | HDAC1HDAC2HRH3S1PR1FFAR4 | |
| SCHEMBL3887696 | 0.81 | HDAC1 (0.40) | HDAC1HDAC2HRH3S1PR1FFAR4 | |
| SCHEMBL3882719 | 0.81 | CACNA1H (0.39) | HDAC1HDAC2HRH3S1PR1FFAR4 | |
| SCHEMBL3684452 | 0.81 | CCNC (0.49) | HDAC1HDAC2HRH3FFAR4PDE4B | |
| SCHEMBL3881161 | 0.80 | FFAR4 (0.46) | HDAC1HDAC2HRH3S1PR1FFAR4 | |
| SCHEMBL3882098 | 0.80 | FAAH (0.40) | HDAC1HDAC2HRH3FFAR4PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | claimed |
| CN-100387576-C | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2008-05-14 | — | — | CN | claimed |
| CN-1653032-A | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2005-08-10 | — | — | CN | claimed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | claimed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | claimed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | claimed |
| EP-1477472-B1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2009-01-14 | — | — | EP | disclosed |
| CN-100387576-C | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2008-05-14 | — | — | CN | disclosed |
| CN-1653032-A | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2005-08-10 | — | — | CN | disclosed |
| US-6867320-B2 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-03-15 | — | — | US | disclosed |
| EP-1477472-A1 | SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044258-A1 | Substituted phenylalkanoic acid derivatives and use thereof | PTGER1, CYSLTR1, PTGS1 | HDAC1 859/4885HDAC2 861/4885HRH3 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.